Pfizer Stock Quote Insights and Financial Performance

Pfizer's stock price has been steadily increasing over the years, with a significant spike in 2020 due to the COVID-19 pandemic.

The company's revenue has been consistently high, reaching a record $51.75 billion in 2020.

Pfizer's strong financial performance has led to a significant increase in its market value, making it one of the largest pharmaceutical companies in the world.

The company's diversified portfolio of products, including vaccines and medicines for various diseases, has contributed to its financial success.

Explore further: Umb Financial Stock

Pfizer's market capitalization is a substantial $152,215,360. This reflects the company's size and influence in the market.

The number of shares outstanding is around 5,666,990, which can impact the stock's price and volatility.

Pfizer's annual sales are a significant $58,496 million, indicating a substantial revenue stream.

Here's a summary of Pfizer's key financial metrics:

Pfizer's price/earnings ratio is 10.11, which can be used to compare the company's stock price to its earnings. This ratio can help investors gauge the stock's value and potential for growth.

A unique perspective: Stock Price

Pfizer's market capitalization is a substantial $152,215,360, a clear indication of the company's size and influence in the pharmaceutical industry.

The company has a total of 5,666,990 shares outstanding, which is a significant number that can impact the stock's price and volatility.

Pfizer's annual sales have been steadily high, reaching $58,496 million in the latest available data.

The company's annual income, also known as net income, is $2,119 million, a respectable figure considering its massive size.

Here's a snapshot of Pfizer's key financial metrics:

Pfizer's price-to-sales ratio is 2.56, which can be a useful metric for investors to gauge the company's valuation relative to its revenue.

Pfizer is a multinational pharmaceutical corporation with a rich history dating back to 1849. The company was founded by Charles Pfizer and Charles Erhart in New York City.

Pfizer has a diverse portfolio of products, including prescription medicines, vaccines, and consumer healthcare products. The company has a significant presence in the global market, with operations in over 150 countries.

Pfizer's revenue has been steadily increasing over the years, with a total revenue of $51.75 billion in 2020. The company's strong financial position allows it to invest in research and development, driving innovation in the pharmaceutical industry.

Pfizer has a strong research and development pipeline, with a focus on developing innovative treatments for various diseases and conditions. The company has a dedicated team of scientists and researchers working on new projects.

Pfizer stock has demonstrated remarkable price performance, with a 1-month period high of $27.57, a 3-month period high of $29.17, and a 52-week period high of $31.54.

Over the past year, Pfizer stock has shown a -0.73% performance since January 26, 2024, which is a relatively stable trend.

According to the Zacks Rank, Pfizer stock has a Strong Buy rating with a 24.35% annualized return, indicating a high probability of success.

Here's a breakdown of the Zacks Rank and its corresponding annualized returns:

The price performance of a stock can be a great indicator of its potential for growth. The 1-Month period shows a low of $25.85 with a 3.44% increase on January 23rd, and a high of $27.57 with a 3.01% decrease on January 7th.

This stock's performance over the past month has been relatively flat, with a gain of only +0.12 (+0.45%) since December 27th. The 3-Month period reveals a low of $24.48 with a 9.23% increase on November 15th, and a high of $29.17 with an 8.33% decrease on October 29th.

The 52-Week period shows a low of $24.48 with a 9.23% increase on November 15th, and a high of $31.54 with a 15.22% decrease on July 30th. The stock's performance over the past year has been somewhat lackluster, with a loss of -0.73 (-2.66%) since January 26th.

Here's a summary of the stock's price performance over different time periods:

The Barchart Technical Opinion rating is a strong indicator of a stock's short-term performance. It's currently a 40% Sell, which suggests that the market is leaning towards selling.

This rating is based on the technical analysis of the stock's charts, and it's giving a Weakest short term outlook on maintaining the current direction.

Long-term indicators, however, fully support a continuation of the trend, which is a reassuring sign for investors looking to hold onto their shares.

Intriguing read: Short Trading Stocks